Singapore-based Raffles Medical Group and Gene Solutions, headquartered in Vietnam, have signed a Memorandum of Understanding (MoU) to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.
Under this partnership, the Raffles Medical Group and Gene Solutions will collaborate to identify patients eligible for pharma-sponsored clinical trials. Patients undergoing Comprehensive Genomic Profiling (CGP) via Gene Solutions will be automatically screened for eligibility.
Raffles Medical Group's Clinical Trials Unit will collaborate closely with local oncologists to facilitate patient enrolment. This initiative aims to make cutting-edge cancer treatments more accessible and support more equitable access to clinical trials across the region.
Through this collaboration, patients in Vietnam and Southeast Asia will have improved opportunities to join innovative cancer studies without traditional barriers. From initial genetic testing and eligibility screening to ongoing clinical care and assistance, patients and their families will receive guidance to navigate complex treatment journeys with confidence and clarity.
Through its Raffles Cancer Centre and dedicated Clinical Trials Unit, Raffles Medical Group has participated in more than 50 international studies, ensuring patients receive access to promising therapies under the highest standards of safety and ethics. Its multi-disciplinary approach and advanced facilities in Singapore make it a trusted destination for complex cancer care and innovative treatments across Southeast Asia.
